Roivant Sciences Ltd.

Symbol: ROIV




Market price today

  • 1.9327

    P/E Ratio

  • 0.0294

    PEG Ratio

  • 8.41B

    MRK Cap

  • 0.00%

    DIV Yield

Roivant Sciences Ltd. (ROIV) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Matthew Gline
Full-time employees:904
Address:11-12 St. James’s Square

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

General Outlook

In simple terms, Roivant Sciences Ltd. has 805.846 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.876% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 39.165%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 35.091%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.591% return, is a testament to Roivant Sciences Ltd.'s adeptness in optimizing resource deployment. Roivant Sciences Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 1.810%. Furthermore, the proficiency of Roivant Sciences Ltd. in capital utilization is underscored by a remarkable 0.683% return on capital employed.

Stock Prices

Roivant Sciences Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $10.52, while its low point bottomed out at $10.15. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Roivant Sciences Ltd.'s stock market.

Liquidity Ratios

Analyzing ROIV liquidity ratios reveals its financial health of the firm. The current ratio of 2779.40% gauges short-term asset coverage for liabilities. The quick ratio (2749.70%) assesses immediate liquidity, while the cash ratio (2723.90%) indicates cash reserves.

Current Ratio2779.40%
Quick Ratio2749.70%
Cash Ratio2723.90%

Profitability Ratios

ROIV profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 3461.24% underscores its earnings before tax deductions. The effective tax rate stands at 0.64%, revealing its tax efficiency. The net income per EBT, 101.38%, and the EBT per EBIT, 88.38%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 3916.52%, we grasp its operational profitability.

Pretax Profit Margin3461.24%
Effective Tax Rate0.64%
Net Income per EBT101.38%
EBT per EBIT88.38%
EBIT per Revenue3916.52%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 27.79, it details the span from stock purchase to revenue. The 27 days it takes to settle debts showcases its creditor relations. Meanwhile, a 27 cash conversion cycle and 195.04% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding2750
Days of Inventory Outstanding125
Operating Cycle311.96
Days of Payables Outstanding839
Cash Conversion Cycle-527
Receivables Turnover1.95
Payables Turnover0.43
Inventory Turnover2.92
Fixed Asset Turnover1.79
Asset Turnover0.02

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.04, and free cash flow per share, -1.05, depict cash generation on a per-share basis. The cash per share value, 8.33, showcases liquidity position. Lastly, the operating cash flow sales ratio, -6.78, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-1.04
Free Cash Flow per Share-1.05
Cash per Share8.33
Operating Cash Flow Sales Ratio-6.78
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-1.65
Short Term Coverage Ratio-14.88
Capital Expenditure Coverage Ratio-314.84
Dividend Paid and Capex Coverage Ratio-55.83
Dividend Payout Ratio0.03

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 6.93%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.08, we discern the balance between debt and equity financing. The long-term debt to capitalization, 6.89%, and total debt to capitalization, 7.68%, ratios shed light on its capital structure. An interest coverage of 133.42 indicates its ability to manage interest expenses.

Debt Ratio6.93%
Debt Equity Ratio0.08
Long Term Debt to Capitalization6.89%
Total Debt to Capitalization7.68%
Interest Coverage133.42
Cash Flow to Debt Ratio-1.65
Company Equity Multiplier1.20

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.09, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.73, reflects the portion of profit attributed to each share. The book value per share, 2.26, represents the net asset value distributed per share, while the tangible book value per share, 2.05, excludes intangible assets.

Revenue Per Share0.09
Net Income Per Share-1.73
Book Value Per Share2.26
Tangible Book Value Per Share2.05
Shareholders Equity Per Share2.26
Interest Debt Per Share0.71
Capex Per Share-0.02

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 10.84%, indicates top-line expansion, while the gross profit growth, 3.96%, reveals profitability trends. EBIT growth, 11.07%, and operating income growth, 11.07%, offer insights into operational profitability progression. The net income growth, -33.10%, showcases bottom-line expansion, and the EPS growth, -25.36%, measures the growth in earnings per share.

Revenue Growth10.84%
Gross Profit Growth3.96%
EBIT Growth11.07%
Operating Income Growth11.07%
Net Income Growth-33.10%
EPS Growth-25.36%
EPS Diluted Growth-25.36%
Weighted Average Shares Growth6.43%
Weighted Average Shares Diluted Growth6.43%
Operating Cash Flow Growth-24.44%
Free Cash Flow Growth-23.15%
10-Year Revenue Growth per Share696.66%
5-Year Revenue Growth per Share696.66%
3-Year Revenue Growth per Share-72.65%
10-Year Operating CF Growth per Share75.12%
5-Year Operating CF Growth per Share75.12%
3-Year Operating CF Growth per Share66.55%
10-Year Net Income Growth per Share64.33%
5-Year Net Income Growth per Share64.33%
3-Year Net Income Growth per Share-130.96%
10-Year Shareholders Equity Growth per Share-32.26%
5-Year Shareholders Equity Growth per Share-32.26%
3-Year Shareholders Equity Growth per Share-76.10%
Receivables Growth386.26%
Inventory Growth116.77%
Asset Growth-7.56%
Book Value per Share Growth-25.92%
Debt Growth69.57%
R&D Expense Growth8.73%
SGA Expenses Growth-22.52%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 4,064,989,428.7, captures the company's total value, considering both debt and equity. Income quality, 0.76, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 9.80, gauges operational efficiency, while the research and development to revenue, 857.07%, highlights investment in innovation. The ratio of intangibles to total assets, 6.06%, indicates the value of non-physical assets, and capex to operating cash flow, 1.50%, measures reinvestment capability.

Enterprise Value4,064,989,428.7
Income Quality0.76
Sales General and Administrative to Revenue9.80
Research and Development to Revenue857.07%
Intangibles to Total Assets6.06%
Capex to Operating Cash Flow1.50%
Capex to Revenue-20.71%
Capex to Depreciation-67.30%
Stock-Based Compensation to Revenue355.39%
Graham Number9.36
Return on Tangible Assets-54.80%
Graham Net Net1.31
Working Capital1,526,139,000
Tangible Asset Value1,462,706,000
Net Current Asset Value1,016,570,000
Average Receivables19,733,500
Average Payables36,206,500
Average Inventory-6,851,000
Days Sales Outstanding195
Days Payables Outstanding1052
Days of Inventory On Hand77

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.37, and the price to book ratio, 1.37, reflect the market's valuation relative to the company's book value. The price to sales ratio, 68.26, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -10.03, and price to operating cash flows, -10.00, gauge market valuation against cash flow metrics.

Price Book Value Ratio1.37
Price to Book Ratio1.37
Price to Sales Ratio68.26
Price Cash Flow Ratio-10.00
Price Earnings to Growth Ratio0.03
Enterprise Value Multiple-14.74
Price Fair Value1.37
Price to Operating Cash Flow Ratio-10.00
Price to Free Cash Flows Ratio-10.03
Price to Tangible Book Ratio3.27
Enterprise Value to Sales66.33
Enterprise Value Over EBITDA-3.67
EV to Operating Cash Flow-4.82
Earnings Yield-23.38%
Free Cash Flow Yield-16.27%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Roivant Sciences Ltd. (ROIV) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 1.933 in 2024.

What is the ticker symbol of Roivant Sciences Ltd. stock?

The ticker symbol of Roivant Sciences Ltd. stock is ROIV.

What is company IPO date?

IPO date of Roivant Sciences Ltd. is 2020-12-08.

What is company current share price?

Current share price is 10.440 USD.

What is stock market cap today?

The market cap of stock today is 8413032240.000.

What is PEG ratio in 2024?

The current 0.029 is 0.029 in 2024.

What is the number of employees in 2024?

In 2024 the company has 904.